Navigation Links
Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
Date:10/31/2013

0, 2012.(g) Net income/expenses from the changes in acquisition-related contingent consideration for the nine months ended September 30, 2013 and 2012 of $33.5 million and $23.2 million, respectively.(h) In-process research and development impairments and other charges for the nine months ended September 30, 2013 of $128.8 million primarily due to the write-off of IPR&D assets relating to the modified-release formulation of ezogabine/retigabine of $93.8 million and IPR&D assets acquired as part of Aton Pharma, Inc. acquisition in May 2010.  In-process research and development impairments and other charges for the nine months ended September 30, 2012 of $149.9 million primarily due to the write-off of IRP&D asset relating to IDP-107 dermatology program, $133.4 million, a $12.0 million payment to terminate research and development with a third party and the termination of an IPR&D program acquired from Ortho Dermatologics, $4.3 million.(i) For the nine months ended September 30, 2013 legal settlement and related fees of $155.2 million primarily relating to a settlement agreement with Anacor Pharmaceuticals, Inc.  For the nine months ended September 30, 2012 legal settlement and related fees of $56.8 million relating to settlements and associated legal fees of patent-related and anti-trust litigations.(j) Restructuring, acquisition-related and other costs of $423.0 million primarily represent costs relating to the acquisitions of Bausch & Lomb Holdings Incorporated, Medicis Pharmaceutical Corporation, Obagi Medical Products, Inc. and other Valeant restructuring and integration initiatives.
These include $192.6 million relating to employee severance costs, $116.1 million relating to duplicative labor, contract terminations, integration consulting,  transition services, and other,  $56.3 million of stock-based compensation, $24.4 million relating to acquisition costs, $14.8 million relating to facility closure costs, $10.0 milli
'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Mallinckrodt plc (NYSE: MNK ) ... a share repurchase program. The open-ended authorization permits the ... plc ordinary shares. "Funding additional initiatives ... as we continue to pursue a range of focused ...
(Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... Research, Inc. issues a,review on Nventa Biopharmaceuticals Corporation ... Candidate for the Treatment of,Diseases Caused by the ... Scimitar,s website: http://www.scimitarequity.com ., About Nventa ... the treatment of viral,infections and cancer, with a ...
... Through Joint Venture Between Bristol-Myers Squibb and ... Its Kind in HIV Treatment -, PRINCETON, N.J. ... Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz 600 mg/emtricitabine ... commercialization in the,27 countries of the European Union, as ...
Cached Medicine Technology:Initiation of Coverage Informational Review Issued by Scimitar Equity Research 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list of ... . , Some types of vehicles cannot be covered under ... blog post to see if their vehicle qualifies for auto insurance ... of the cars that cannot be covered by a plan. Clients ...
(Date:12/26/2014)... December 26, 2014 The US represents the ... report. In 2013, GlobalData’s forecast estimates that sales of branded ... market due to the high incidence of the disease, high ... 5EU, Japan, and China. Increased sales of CRC therapies over ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... , BEDFORD, N.H., Oct. 1 Emerson Ecologics, ... Research as their exclusive distributor. Effective immediately, Emerson ... the complete line of Crayhon Research products. ... supplements for the brain and body, available to ...
... Oct. 1 Two interactive computer tools released today ... help emergency planners and responders select and run alternate ... experiencing a surge in seriously ill patients requiring acute ... to alternate care sites. , Alternate care ...
... Smile, a worldwide children,s medical charity, will honor Jessica, Ashlee, ... Honorable Richard J. Riordan, Roselyn Sanchez and Eric Winter at ... Beverly Hilton Hotel. Access Hollywood,s Billy Bush will ... , Operation Smile Co-founders, Dr. Bill and Kathy Magee, ...
... with certain birth defects, research shows , THURSDAY, Oct. ... likely to give birth to babies with heart defects, a ... and Prevention researchers analyzed data on 6,440 infants with congenital ... took part in the National Birth Defects Prevention Study. , ...
... presentations available through live Webcasts from Honolulu ... (ADA) interactive Education in the Round (EIR) live-patient ... the convention center to thousands of North American dental ... and the American Dental Education Association (ADEA) recently announced ...
... (MIAW) is Oct. 4-10, 2009 and as part of its observance, ... is calling attention to a program now airing on PBS, " ... Observed annually the first full week in October, Congress established MIAW ... such as major depression, bipolar disorder, and schizophrenia ...
Cached Medicine News:Health News:Crayhon Research Now Available Exclusively Through Emerson Ecologics 2Health News:New Tools Help Emergency Planners Select Alternate Care Facilities and Transfer Patients During Disasters 2Health News:Operation Smile to Honor the Simpson Family, Stephen Berman, the Honorable Richard J. Riordan, Roselyn Sanchez and Eric Winter at 8th Annual Smile Gala in Los Angeles 2Health News:Pre-Pregnancy Weight Linked to Babies' Heart Problems 2Health News:Dental Students, Faculty Gain Live Remote Access to ADA Annual Session Courses 2Health News:Dental Students, Faculty Gain Live Remote Access to ADA Annual Session Courses 3Health News:Mental Illness Awareness Week: What You Should Know, Including PBS Broadcasts, Oct. 4-10 2
Terumo's Outlook offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... INFINITI 4F, 5F, and ... catheters is ideal for ... incorporate state-of-the-art technology and ... deliver better responsiveness, optimal ...
Medicine Products: